---
pmid: '24725412'
title: Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson's
  disease.
authors:
- Martin I
- Kim JW
- Lee BD
- Kang HC
- Xu JC
- Jia H
- Stankowski J
- Kim MS
- Zhong J
- Kumar M
- Andrabi SA
- Xiong Y
- Dickson DW
- Wszolek ZK
- Pandey A
- Dawson TM
- Dawson VL
journal: Cell
year: '2014'
full_text_available: false
pmcid: PMC4040530
doi: 10.1016/j.cell.2014.01.064
---

# Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson's disease.
**Authors:** Martin I, Kim JW, Lee BD, Kang HC, Xu JC, Jia H, Stankowski J, Kim MS, Zhong J, Kumar M, Andrabi SA, Xiong Y, Dickson DW, Wszolek ZK, Pandey A, Dawson TM, Dawson VL
**Journal:** Cell (2014)
**DOI:** [10.1016/j.cell.2014.01.064](https://doi.org/10.1016/j.cell.2014.01.064)
**PMC:** [PMC4040530](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4040530/)

## Abstract

1. Cell. 2014 Apr 10;157(2):472-485. doi: 10.1016/j.cell.2014.01.064.

Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in 
Parkinson's disease.

Martin I(1), Kim JW(2), Lee BD(3), Kang HC(4), Xu JC(5), Jia H(2), Stankowski 
J(1), Kim MS(6), Zhong J(7), Kumar M(5), Andrabi SA(1), Xiong Y(5), Dickson 
DW(8), Wszolek ZK(9), Pandey A(10), Dawson TM(11), Dawson VL(12).

Author information:
(1)Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, 
Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; 
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, 
MD 21205, USA; Adrienne Helis Malvin Medical Research Foundation, New Orleans, 
LA 70130, USA.
(2)Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, 
Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; 
Department of Physiology, Johns Hopkins University School of Medicine, 
Baltimore, MD 21205, USA; Adrienne Helis Malvin Medical Research Foundation, New 
Orleans, LA 70130, USA.
(3)Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, 
Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; 
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, 
MD 21205, USA; Age-Related and Brain Disease Research Center, Department of 
Neuroscience, Kyung Hee University, Seoul 130-701, South Korea.
(4)Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, 
Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; 
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, 
MD 21205, USA; Department of Physiology, Ajou University School of Medicine, 
Suwon 443-749, South Korea.
(5)Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, 
Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; 
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, 
MD 21205, USA.
(6)Department of Biological Chemistry, Johns Hopkins University School of 
Medicine, Baltimore, MD 21205, USA; McKusick Nathans Institute of Genetic 
Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
(7)McKusick Nathans Institute of Genetic Medicine, Johns Hopkins University 
School of Medicine, Baltimore, MD 21205, USA.
(8)Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
(9)Department of Neurology, Mayo Clinic, Jacksonville, FL 32224, USA.
(10)Department of Biological Chemistry, Johns Hopkins University School of 
Medicine, Baltimore, MD 21205, USA; Department of Pathology, Johns Hopkins 
University School of Medicine, Baltimore, MD 21205, USA; Department of Oncology, 
Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; McKusick 
Nathans Institute of Genetic Medicine, Johns Hopkins University School of 
Medicine, Baltimore, MD 21205, USA; Adrienne Helis Malvin Medical Research 
Foundation, New Orleans, LA 70130, USA; Diana Helis Henry Medical Research 
Foundation, New Orleans, LA 70130, USA.
(11)Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, 
Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; 
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, 
MD 21205, USA; Solomon H. Snyder Department of Neuroscience, Johns Hopkins 
University School of Medicine, Baltimore, MD 21205, USA; Adrienne Helis Malvin 
Medical Research Foundation, New Orleans, LA 70130, USA. Electronic address: 
tdawson@jhmi.edu.
(12)Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, 
Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; 
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, 
MD 21205, USA; Department of Physiology, Johns Hopkins University School of 
Medicine, Baltimore, MD 21205, USA; Solomon H. Snyder Department of 
Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21205, 
USA; Adrienne Helis Malvin Medical Research Foundation, New Orleans, LA 70130, 
USA. Electronic address: vdawson@jhmi.edu.

Comment in
    Cell. 2014 Apr 10;157(2):291-293. doi: 10.1016/j.cell.2014.03.043.
    Mov Disord. 2014 Jul;29(8):990. doi: 10.1002/mds.25932.

Mutations in leucine-rich repeat kinase 2 (LRRK2) are a common cause of familial 
and sporadic Parkinson's disease (PD). Elevated LRRK2 kinase activity and 
neurodegeneration are linked, but the phosphosubstrate that connects LRRK2 
kinase activity to neurodegeneration is not known. Here, we show that ribosomal 
protein s15 is a key pathogenic LRRK2 substrate in Drosophila and human neuron 
PD models. Phosphodeficient s15 carrying a threonine 136 to alanine substitution 
rescues dopamine neuron degeneration and age-related locomotor deficits in 
G2019S LRRK2 transgenic Drosophila and substantially reduces G2019S 
LRRK2-mediated neurite loss and cell death in human dopamine and cortical 
neurons. Remarkably, pathogenic LRRK2 stimulates both cap-dependent and 
cap-independent mRNA translation and induces a bulk increase in protein 
synthesis in Drosophila, which can be prevented by phosphodeficient T136A s15. 
These results reveal a novel mechanism of PD pathogenesis linked to elevated 
LRRK2 kinase activity and aberrant protein synthesis in vivo.

Copyright Â© 2014 Elsevier Inc. All rights reserved.

DOI: 10.1016/j.cell.2014.01.064
PMCID: PMC4040530
PMID: 24725412 [Indexed for MEDLINE]
